NASDAQ:GNPX

Genprex Q1 2026 Earnings Results & Report

Genprex logo
$1.45 -0.22 (-13.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+1.72%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genprex reported Q1 2026 earnings on May 13, 2026. The company reported EPS of -$14.08.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Genprex EPS Results

Actual EPS
-$14.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Genprex Q1 2026 Earnings FAQ

Genprex (NASDAQ:GNPX) reported earnings of -$14.08 per share for Q1 2026. The report was announced on Wednesday, May 13, 2026.

Genprex's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genprex on the company's earnings history page.

Genprex Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company developing treatments for cancer and diabetes. The company is based in Austin, Texas, and its work focuses on using genetic material to address diseases with significant unmet medical needs.

Its lead cancer candidate, REQORSA (quaratusugene ozeplasmid), is an investigational, non-viral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. Genprex has studied REQORSA in clinical trials for non-small cell lung cancer, including in combination with other cancer therapies.

Genprex is also developing an investigational gene therapy program for diabetes. Its candidates remain in development, and the company’s therapies are not approved for commercial use.

View Genprex Profile